Disproportionate rise in clostridium difficile -associated hospitalizations among us youth with inflammatory bowel disease, 1997-2011

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 4, 2015, Pages 486-492

  Sandberg, Kelly C ^a   Davis, Matthew M ^b   Gebremariam, Achamyeleh ^b   Adler, Jeremy ^a  

^a Dayton Children's Hospital   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Clostridium difficile; inflammatory bowel disease; national trends; Nationwide Inpatient Sample; variance weighted regression

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; CROHN DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HOSPITAL CARE; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; AGE; CLOSTRIDIUM INFECTIONS; COMPLICATION; ECONOMICS; HOSPITAL COST; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; PREVALENCE; UNITED STATES; YOUNG ADULT;

CLOSTRIDIUM DIFFICILE;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLECTOMY; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; LENGTH OF STAY; MALE; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84927176835     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000636     Document Type: Article

References (49)

1. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15:1554-80.
2. Forster AJ, Taljaard M, Oake N, et al. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. Can Med Assoc J 2012;184:37-42.
3. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14:929-31.
4. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205-10.
5. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:976-83.
6. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443-50.
7. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009;7:981-7.
8. Gerding DN. Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents 2009;33 (suppl 1):S2-8.
9. Sandberg KC, Davis MM, Gebremariam A, et al. Increasing hospitalizations in inflammatory bowel disease among children in the United States, 1988-2011. Inflamm Bowel Dis 2014;20:1754-60.
10. Pant C, Anderson MP, Deshpande A, et al. Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1080-5.
11. AHRQ. Overview of the nationwide inpatient sample. http://www.hcupus. ahrq.gov/nisoverview.jsp. Accessed August 29, 2014.
12. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004;114:786-92.
13. Patel MS, Gebremariam A, Davis MM. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol 2008;29: 1157-63.
14. Zickafoose JS, Benneyworth BD, Riebschleger MP, et al. Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States. Arch Pediatr Adolesc Med 2012;166:350-5.
15. AHRQ. Requirements for publishing with HCUP data. http://www. hcup-us.ahrq.gov/db/publishing.jsp. Accessed August 29, 2014.
16. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-94.
17. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol 2008;103:2789-98.
18. Nguyen GC, Bayless TM, Powe NR, et al. Race and health insurance are predictors of hospitalized Crohn's disease patients undergoing bowel resection. Inflamm Bowel Dis 2007;13:1408-16.
19. Pant C, Anderson MP, Deshpande A, et al. Trends in hospitalizations of children with inflammatory bowel disease within the United States from 2000 to 2009. J Investig Med 2013;61:1036-8.
20. Deshpande A, Pant C, Anderson MP, et al. Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence. Pediatr Infect Dis J 2013;32:1138-40.
21. Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011;165:451-7.
22. Dubberke ER, Reske KA, McDonald LC, et al. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis 2006;12:1576-9.
23. Bureau of Labor Statistics. Consumer Price Index. http://www.bls.gov/ cpi. Accessed April 2, 2014.
24. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures United States, 2000-2009. J Am Med Assoc 2012;307:1934-40.
25. Benneyworth BD, Gebremariam A, Clark SJ, et al. Inpatient health care utilization for children dependent on long-term mechanical ventilation. Pediatrics 2011;127:e1533-41.
26. Weisberg S.Wiley Series in Probability and Statistics. 3rd ed. Hoboken, NJ: Wiley-Interscience; 2005.
27. Smith LC, Ratard R. Clostridium difficile hospitalizations in Louisiana: a 10 year review. J La State Med Soc 2011;163:192-5.
28. Jen M-H, Saxena S, Bottle A, et al. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:1322-31.
29. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospitalacquired Clostridium difficile disease in the United States, 1987-20001. J Infect Dis 2004;189:1585-9.
30. Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci 2014.
31. Murphy CR, Avery TR, Dubberke ER, et al. Frequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden. Infect Control Hosp Epidemiol 2012;33:20-8.
32. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-64.
33. Mezoff EA, Cohen MB. Acid suppression and the risk of Clostridium difficile infection. J Pediatr 2013;163:627-30.
34. Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea? J Hosp Infect 2008;70:1-6.
35. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39.
36. Shea KM. Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics. Pediatrics 2004;114: 862-8.
37. van den Bogaard AE, Stobberingh EE. Antibiotic usage in animals. Drugs 1999;58:589-607.
38. Boix C, Ibáñez M, Zamora T, et al. Identification of new omeprazole metabolites in wastewaters and surface waters. Sci Total Environ 2014;468-469:706-14.
39. Morais SA, Delerue-Matos C, Gabarrell X. An uncertainty and sensitivity analysis applied to the prioritisation of pharmaceuticals as surface water contaminants from wastewater treatment plant direct emissions. Sci Total Environ 2014;490:342-50.
40. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. Water Res 2009;43:363-80.
41. Spongberg AL,Witter JD. Pharmaceutical compounds in the wastewater process stream in Northwest Ohio. Sci Total Environ 2008;397:148-57.
42. Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012;36:1032-9.
43. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010;55:415-20.
44. Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008;121:1099-106.
45. Kolho K-L, Turner D. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol 2013;2013:179024.
46. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010;59:1207-12.
47. van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012;18:2018-25.
48. Turner D, Griffiths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 2013;11: 1460-5.
49. Gray FL, Turner CG, Zurakowski D, et al. Predictive value of the Pediatric Ulcerative Colitis Activity Index in the surgical management of ulcerative colitis. J Pediatr Surg 2013;48:1540-5.